Live data · NADAC + Part D CY24 · reviewed daily

Abacavir (Abacavir)

Abacavir blocks HIV replication by inhibiting reverse transcriptase.

First FDA approval1999-01-28
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$4.2M in CY2024 Part D spend23K claims · 4K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.601/unit
13 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.604
Across all dosage forms in distribution.
Highest NADAC
$0.641
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Abacavir used for?

Abacavir blocks HIV replication by inhibiting reverse transcriptase.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book
Is there a generic for Abacavir?

Yes. 7 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book
How much does my plan pay for Abacavir?

Across 329 Part D plans, Abacavir averages $0.604/unit (NADAC). Lowest available: $0.601/unit. Highest in distribution: $0.641/unit.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book
Is Abacavir on the FDA shortage list?

No. Abacavir is not currently on the FDA Drug Shortage Database.

Sources: CMS Part D Spending CY24 · CMS NADAC weekly · FDA Orange Book

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Related questions.

Q&A librarySourced · reviewed quarterly
pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?
Browse all canonical questions →

Same class. Different math.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor6 alternatives in D1
01
$136.67Lowest NADAC
0Generic mfrs
—CY24 Part D spend
Compare →
02
Emtricitabine
 Brand: Emtriva
$12.25Lowest NADAC
2Generic mfrs
$3.0MCY24 Part D spend
Compare →
03
Emtricitabine and Tdf
 Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
—Lowest NADAC
0Generic mfrs
—CY24 Part D spend
Compare →
04
$74.85Lowest NADAC
1Generic mfrs
—CY24 Part D spend
Compare →
05
$0.451Lowest NADAC
10Generic mfrs
—CY24 Part D spend
Compare →
06
$130.38Lowest NADAC
0Generic mfrs
—CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh14 Jul 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (13 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.